Gout: possibilities of treatment optimization
Aim. To consider new mechanisms of gout pathogenesis of and possibilities of influencing the pathological process. Gout is a chronic joint disease caused by the deposition of monosodium urate crystals in various tissues and subsequent inflammation in individuals with hyperuricemia, caused by exocrin...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2024-12-01
|
| Series: | Klinicist |
| Subjects: | |
| Online Access: | https://klinitsist.abvpress.ru/Klin/article/view/618 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849336140418514944 |
|---|---|
| author | A. A. Klimenko N. A. Shostak D. A. Andriyashkina A. A. Kondrashov |
| author_facet | A. A. Klimenko N. A. Shostak D. A. Andriyashkina A. A. Kondrashov |
| author_sort | A. A. Klimenko |
| collection | DOAJ |
| description | Aim. To consider new mechanisms of gout pathogenesis of and possibilities of influencing the pathological process. Gout is a chronic joint disease caused by the deposition of monosodium urate crystals in various tissues and subsequent inflammation in individuals with hyperuricemia, caused by exocrine and/or genetic factors. In recent years, new knowledge about gout diagnostics, genetics, pathogenesis, comorbidities and various data indicate new strategies to improve control of the disease and its exacerbations, as well as to prevent comorbid conditions. The discovery of new mechanisms concerning sodium monourate crystal-induced inflammation, proposed new methods of treating not only gout, but also other systemic diseases, including renal and cardiovascular diseases using xanthine oxidase inhibitors, including febuxostat. The case of colchicine is very indicative, which recently, taking into account the significant results of laboratory and clinical experiments, received approval from the US Federal Food and Drug Administration for the Prevention of cardiovascular Diseases. This has provided opportunities for the combinedadministration of febuxostat and colchicine to treat gout, recurrent arthritis attacks and reduce the risk of cardiovascular complications. |
| format | Article |
| id | doaj-art-8f62ab3df69b4cadaa6e5487b0ea281b |
| institution | Kabale University |
| issn | 1818-8338 |
| language | Russian |
| publishDate | 2024-12-01 |
| publisher | ABV-press |
| record_format | Article |
| series | Klinicist |
| spelling | doaj-art-8f62ab3df69b4cadaa6e5487b0ea281b2025-08-20T03:45:04ZrusABV-pressKlinicist1818-83382024-12-01183697810.17650/1818-8338-2024-18-3-K723445Gout: possibilities of treatment optimizationA. A. Klimenko0N. A. Shostak1D. A. Andriyashkina2A. A. Kondrashov3N.I. Pirogov National Research Medical University, Ministry of Health of Russia; N.I. Pirogov City Clinical Hospital No.1, Moscow Healthcare DepartmentN.I. Pirogov National Research Medical University, Ministry of Health of RussiaN.I. Pirogov National Research Medical University, Ministry of Health of RussiaN.I. Pirogov National Research Medical University, Ministry of Health of RussiaAim. To consider new mechanisms of gout pathogenesis of and possibilities of influencing the pathological process. Gout is a chronic joint disease caused by the deposition of monosodium urate crystals in various tissues and subsequent inflammation in individuals with hyperuricemia, caused by exocrine and/or genetic factors. In recent years, new knowledge about gout diagnostics, genetics, pathogenesis, comorbidities and various data indicate new strategies to improve control of the disease and its exacerbations, as well as to prevent comorbid conditions. The discovery of new mechanisms concerning sodium monourate crystal-induced inflammation, proposed new methods of treating not only gout, but also other systemic diseases, including renal and cardiovascular diseases using xanthine oxidase inhibitors, including febuxostat. The case of colchicine is very indicative, which recently, taking into account the significant results of laboratory and clinical experiments, received approval from the US Federal Food and Drug Administration for the Prevention of cardiovascular Diseases. This has provided opportunities for the combinedadministration of febuxostat and colchicine to treat gout, recurrent arthritis attacks and reduce the risk of cardiovascular complications.https://klinitsist.abvpress.ru/Klin/article/view/618goutgouty arthritischronic kidney diseasediabetes mellituscolchicinexanthine oxidase inhibitorfebuxostatallopurinol |
| spellingShingle | A. A. Klimenko N. A. Shostak D. A. Andriyashkina A. A. Kondrashov Gout: possibilities of treatment optimization Klinicist gout gouty arthritis chronic kidney disease diabetes mellitus colchicine xanthine oxidase inhibitor febuxostat allopurinol |
| title | Gout: possibilities of treatment optimization |
| title_full | Gout: possibilities of treatment optimization |
| title_fullStr | Gout: possibilities of treatment optimization |
| title_full_unstemmed | Gout: possibilities of treatment optimization |
| title_short | Gout: possibilities of treatment optimization |
| title_sort | gout possibilities of treatment optimization |
| topic | gout gouty arthritis chronic kidney disease diabetes mellitus colchicine xanthine oxidase inhibitor febuxostat allopurinol |
| url | https://klinitsist.abvpress.ru/Klin/article/view/618 |
| work_keys_str_mv | AT aaklimenko goutpossibilitiesoftreatmentoptimization AT nashostak goutpossibilitiesoftreatmentoptimization AT daandriyashkina goutpossibilitiesoftreatmentoptimization AT aakondrashov goutpossibilitiesoftreatmentoptimization |